Cierre percutáneo de la auriculilla izquierda con dispositivo Watchman: opción para pacientes con fibrilación auricular y alto riesgo de sangrado por anticoagulación
DOI:
https://doi.org/10.17533/udea.iatreia.v28n3a11Palabras clave:
apéndice atrial, coagulación sanguínea, fibrilación atrialResumen
La fibrilación auricular es la arritmia más común en la práctica clínica, con una prevalencia estimada de 1% a 2% en la población general. La anticoagulación sigue siendo parte fundamental de su tratamiento para la prevención de eventos cerebrovasculares (ECV) embólicos, pero está contraindicada aproximadamente en el 20% de los pacientes. Reportamos el caso de un paciente con fibrilación auricular no valvular con puntaje alto de riesgo para ECV, pero con antecedente de sangrado intraparenquimatoso cerebral y muy alto riesgo de sangrado con la anticoagulación a largo plazo; se hizo con éxito y sin complicaciones el cierre percutáneo de la auriculilla izquierda con el dispositivo Watchman.
Descargas
Citas
(1.) Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul;114(2):119-25. Erratum in: Circulation. 2006 Sep;114(11):e498.
(2.) Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb;123(4):e18-e209. DOI 10.1161/CIR.0b013e3182009701. Erratum in: Circulation. 2011 Oct;124(16):e426. Circulation. 2011 Feb 15;123(6):e240.
(3.) Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K. The atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994 Jul;154(13):1449-57. Erratum in: Arch Intern Med 1994 Oct 10;154(19):2254.
(4.) Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun;285(22):2864-70.
(5.) Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. DOI 10.1378/chest.09-1584.
(6.) ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun;367(9526):1903-12.
(7.) Bergmann MW, Landmesser U. Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. EuroIntervention. 2014 Aug;10(4):497-504. DOI 10.4244/EIJV10I4A86.
(8.) Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005 Jul;46(1):9-14.
(9.) Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009 Aug;374(9689):534-42. DOI 10.1016/S0140-6736(09)61343-X. Erratum in: Lancet. 2009 Nov;374(9701):1596.
(10.) Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014 Jul;64(1):1-12. DOI 10.1016/j.jacc.2014.04.029. Erratum in: J Am Coll Cardiol. 2014 Sep;64(11):1186.
(11.) Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011 Feb;123(4):417-24. DOI 10.1161/CIR-CULATIONAHA.110.976449.
(12.) Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Deve-loped with the special contribution of the Euro-pean Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. DOI 10.1093/eurheartj/ehs253. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.
(13.) Waksman R, Pendyala LK. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy. Am J Cardiol. 2015 Feb;115(3):378-84. DOI 10.1016/j.amjcard.2014.11.011.
(14.) Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013 Jun;61(25):2551-6. DOI 10.1016/j.jacc.2013.03.035.
(15.) Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomström-Lundqvist C, et al. Left atrial appen-dage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. Europace. 2015 Apr;17(4):642-6. DOI 10.1093/europace/euv069.
(16.) Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke preven-tion in patients with nonvalvular atrial fibrillation. Circulation. 2013 Jun;127(24):2414-23. DOI 10.1161/CIRCULATIONAHA.112.000920.
(17.) Viles-Gonzalez JF, Kar S, Douglas P, Dukkipati S, Feldman T, Horton R, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) subs-tudy. J Am Coll Cardiol. 2012 Mar;59(10):923-9. DOI 10.1016/j.jacc.2011.11.028.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2015 Iatreia
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
Los artículos publicados en la revista están disponibles para ser utilizados bajo la licencia Creative Commons, específicamente son de Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.
Los trabajos enviados deben ser inéditos y suministrados exclusivamente a la Revista; se exige al autor que envía sus contribuciones presentar los formatos: presentación de artículo y responsabilidad de autoría completamente diligenciados.
